Emergent gains on anthrax vaccine contract

Emergent BioSolutions Inc. (NYSE:EBS) jumped $3.33 (16%) to $24.77 on Thursday after the U.S. Government said it intends to award the company a new contract for 44.8 million doses BioThrax anthrax vaccine over five years. Emergent would not disclose the potential value of the contract, which is expected to be finalized next quarter. ...